Biogen is bolstering its strategy of selling biosimilars with a $100 million deal for rights to two eye products from Samsung Bioepis. The drug maker is also expanding its biosimilar scope to include China. Under the agreement announced this week, Biogen will pay Samsung Bioepis $100 million up front for the rights to SB11, a drug that’s biologically similar to Roche’s drug Lucentis; and SB15, which references the Regeneron drug Eylea. The deal also expands Biogen’s commercialization rights for three biosimilars for inflammation. Alert readers will recall that last year Biogen paid $700 million to boost its ownership position in Samsung Bioepis to 49.9%. Learn More